Recent Updates
Recently added Catalysts
SPRO Neutral Sentiment

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Wednesday, March 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spero Therapeutics announced that it will report its financial results for the fourth quarter and full year 2025 on March 26, 2026, after market close. The company focuses on developing treatments for rare diseases and areas with significant unmet medical needs. No conference call will be held to discuss these results. The announcement reflects Spero's ongoing commitment to transparency with its investors.
Price reaction · baseline $2.58 (2026-03-17 close) · hit after-hours · clean, no other SPRO news in the window
day 0 close · peak
-4.7%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
7.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromide
Phase 1 · Renal Impairment

Full Press Release Details

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.
Investor Relations Contact:

Frequently Asked Questions

When will Spero Therapeutics report its financial results?

Spero Therapeutics will report its financial results on March 26, 2026.

What time will the financial results be announced?

The financial results will be announced after market close.

Will Spero Therapeutics hold a conference call?

No, the company does not plan to host a conference call.

Where is Spero Therapeutics located?

Spero Therapeutics is based in Cambridge, Massachusetts.

What is the focus of Spero Therapeutics?

Spero Therapeutics specializes in treatments for rare diseases and high unmet need.

ShareAdd on Google
Tags: SPRO Viatris Investor Conferences Healthcare Spero Therapeutics financial results business update rare diseases
Last updated: Mar 18, 2026

Biotech snapshot

Cash runway
$51M liquidity · $2M/mo burn
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromidePhase 1
Renal Impairment →

Catalyst track record

+8%
best trade around SPRO's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for SPRO.

See every catalyst's timing & PoA →